NEULANDLAB2024-10-012024-12-31 NEULANDLAB2024-10-012024-12-31 NEULANDLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member NEULANDLAB2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member NEULANDLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member NEULANDLAB2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member NEULANDLAB2024-12-31 NEULANDLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member NEULANDLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member NEULANDLAB2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member NEULANDLAB2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524558 NEULANDLAB NOTLISTED Neuland Laboratories Limited Equity 2024-04-01 2025-03-31 2025-02-10 2025-01-23 INR Lakhs Third quarter 14:15:00 16:00:00 2025-02-10 2025-02-10 Not applicable Single segment Manufacturing of Active Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 3980318000.00 39056000.00 4019374000.00 1454412000.00 0.00 209453000.00 693412000.00 22167000.00 163003000.00 757058000.00 3299505000.00 719869000.00 557780000.00 1277649000.00 249510000.00 12271000.00 261781000.00 0.00 1015868000.00 0.00 0.00 0.00 0.00 1015868000.00 -25000.00 1015843000.00 0.00 0.00 0.00 0.00 129005000.00 10 79.18 79.18 0.00 0.00 79.18 79.18 1. The financial results for the quarter and nine months ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 10, 2025. 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. 4. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments . 5. During the period, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the quarter ended June 30, 2024: Rs. 2,062.56 lakhs and for the quarter ended December 31, 2024: Rs. 5,577.80 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. 6. The EPS for quarters has not been annualised. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 11484773000.00 130450000.00 11615223000.00 4335653000.00 0.00 271726000.00 2055473000.00 59504000.00 486547000.00 2100062000.00 9308965000.00 2306258000.00 764036000.00 3070294000.00 677435000.00 69837000.00 747272000.00 0.00 2323022000.00 0.00 0.00 0.00 0.00 2323022000.00 -2484000.00 2320538000.00 0.00 0.00 0.00 0.00 129005000.00 10 181.06 181.06 0.00 0.00 181.06 181.06 Manufacturing expenses 393380000.00 Other Expenses 363678000.00 Manufacturing expenses 1177797000.00 Other Expenses 922265000.00 Re-measurement gain/(loss) on defined benefit plans 0.00 Equity instruments through other comprehensive income 0.00 Re-measurement gain/(loss) on defined benefit plans -5308000.00 Equity instruments through other comprehensive income 136000.00 0.00 -5172000.00 0.00 -1302000.00 Exchange differences in translating the financial statements of foreign operations -25000.00 Exchange differences in translating the financial statements of foreign operations 1386000.00 -25000.00 1386000.00 0.00 0.00